




The relative strengths and weaknesses of Diamedica Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Diamedica Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 161% points. The greatest weakness of Diamedica Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 334%, being 119% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	44,610
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,390
Liabilities, Non-Current	237
Other Assets	1,587
Other Compr. Net Income	17
Other Expenses	30
Other Liabilities	0
Other Net Income	2,267
Other Revenues	0
Property and Equipment	148
Research and Development	19,057
Selling, General and Administrative Expense	7,624

Output Variable	Value in 1000 USD
Assets	46,345
Liabilities	5,627
Expenses	26,711
Revenues	0
Stockholders Equity	40,718
Net Income	-24,444
Comprehensive Net Income	-24,436
BaseVar	40,484
ECR before Limited Liability	248%
Economic Capital Ratio	334%